CervoMed completes enrollment in Phase 2 nfvPPA dementia trial

July 9, 2026 7:30 AM

CervoMed Inc. (NASDAQ: CRVO) has completed enrollment in its Phase 2a clinical trial of neflamapimod for nonfluent variant primary progressive ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found